Text Size

The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2005 by Glostrup University Hospital, Copenhagen.
Recruitment status was  Recruiting
Sponsor:
Collaborators:
Rigshospitalet, Denmark
University of Copenhagen
Information provided by:
Glostrup University Hospital, Copenhagen
ClinicalTrials.gov Identifier:
NCT00273000
First received: January 6, 2006
Last updated: September 7, 2006
Last verified: October 2005
History of Changes
  Purpose

The purpose of this study is to study the effect of GLP-2 on mesenteric bloodflow in healthy adults by the use of ultrasound., it is the hypothesis that GLP-2 vil increase the bloodflow.


Condition Intervention
Healthy
 Drug: GLP-2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Pharmacokinetics/Dynamics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Health Services Research
Official Title: The Importance of Glucagon-Like Peptide-2 (GLP-2)in Mesenteric Bloodflow in Humans

Resource links provided by NLM:

Drug Information available for: Glucagon
U.S. FDA Resources

Further study details as provided by Glostrup University Hospital, Copenhagen:

Estimated Enrollment: 10
Study Start Date: January 2006
Detailed Description:

The investigation will include 10 testpersons.

It will be a 2 fase study over 2 days.

day 1: The testperson will meet fasting, and take in a standard liquid meal, after this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

day 2:The testperson will meet fasting, there wil be administered intraveneous GLP-2 in 3 increasing doses over 3 x 45 min.and one subcutaneous dose. During this the bloodflow in a mesenteric artery will be measured by use of ultrasonic technique. Bloodsamples will be taken regular in a total wolumne of 200 ml.

  Eligibility

Ages Eligible for Study:   18 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • healthy

Exclusion Criteria:

  • use of drugs
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00273000

Contacts
Contact: Lasse Bremholm Hansen, MD 004560927874 hoersted-bremholm@webspeed.dk

Locations
Denmark
Rigshospitalet Recruiting
Copenhagen, Copenhagen City, Denmark, 2100
Contact: Lasse Bremholm Hansen, MD     004560927874     hoersted-bremholm@webspeed.dk    
Sub-Investigator: Mads Hornum, MD            
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Rigshospitalet, Denmark
University of Copenhagen
Investigators
Principal Investigator: Mads Hornum, MD Glostrup University Hospital, Copenhagen
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00273000     History of Changes
Other Study ID Numbers: GLP-2, MBF
Study First Received: January 6, 2006
Last Updated: September 7, 2006
Health Authority: Denmark: National Board of Health

Additional relevant MeSH terms:
Glucagon
Glucagon-Like Peptide 1
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
 Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses
Incretins

ClinicalTrials.gov processed this record on May 22, 2013